ArticleApoptosis : an international journal on programmed cell death2026
SPAG5 promotes ferroptosis and enhances chemotherapy efficacy in locally advanced colorectal cancer via upregulating intracellular ROS levels.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC) has a high incidence and mortality rate worldwide, with chemotherapy being a cornerstone of treatment for locally advanced CRC patients (LACRC). Despite the relatively high efficacy of chemotherapy regimens like FOLFOX and CAPEOX, the resistance of chemotherapy remains a significant challenge. In this study, we identified sperm associated antigen 5 (SPAG5) as a potential therapeutic target in LACRC patients. High SPAG5 expression was correlated with improved progression-free survival (PFS) and overall survival (OS) in CRC patients receiving chemotherapy, as demonstrated by analyses of multiple cohorts, including TCGA, GEO and FUSCC. Mechanistically, SPAG5 overexpression promoted ferroptosis in CRC cells, enhancing chemotherapy efficacy through increased reactive oxygen species (ROS). SPAG5 depletion reduced ROS levels, attenuated ferroptosis, and decreased the cytotoxic effects of chemotherapy. These results indicate that SPAG5 can modulate ROS-dependent ferroptosis to enhance the chemotherapeutic response. Furthermore, inhibition of ROS reversed the chemotherapy-sensitizing effect mediated by SPAG5. Together, these findings suggest that SPAG5 may serve as a promising biomarker and therapeutic target to potentiate the cytotoxic effects of chemotherapy in LACRC patients.
Indexed as
Identifiers
41774258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.